NCT01466036View on ClinicalTrials.gov

Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

August 31, 2021

Study Completion Date

December 31, 2023

Conditions
Carcinoid TumorPancreatic Neuroendocrine Tumor
Interventions
DRUG

Cabozantinib

60 mg QD orally in cycles of 28 days

Trial Locations (2)

02214

Massachusetts General Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER

NCT01466036 - Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | Biotech Hunter | Biotech Hunter